Biomea Fusion, Inc. (NasdaqGS: BMEA)
Health Care · Biotechnology · US
$1.37
+0.74% today · -25.1% 1Y
Biomea Fusion, Inc. (NasdaqGS: BMEA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $99.30M and employs 40 people.
Over the last twelve months the share price has lost 25.1%, trading between 0.87 and 2.99.
Tweenvest scores Biomea Fusion, Inc. across four factors: quality 26/100. Its strongest factor is quality.
BMEA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $99.30M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.47
- Dividend yield
- —
- Beta (5Y)
- -0.30
- 52-week high
- $2.99
- 52-week low
- $0.87
- Avg volume (3M)
- —
- Shares outstanding
- 72.48M
- Employees
- 40
- Next earnings
- —
About Biomea Fusion, Inc.
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
- Founded
- 2017
- Listed since
- Apr 16, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.